Wednesday, October 05, 2022 8:01:20 AM
Literature Database
Intraoperative use of CytoSorb in a mitral valve replacement redo procedure due to infective endocarditis
Darío Andrade1, David Orozco-Vinasco2 | 1Department of Cardiac Surgery, Clínica Colsubsidio Calle 100, Bogota, Colombia | 2Department of Cardiovascular Anesthesia, Clínica Colsubsidio Calle 100, Bogota, Colombia
10/05/2022
Reduction in catecholaminesAnticoagulation HeparinCardiac surgeryCase of the weekCase reportCPBEndocarditisInflammatory parametersIntra-Op
Download documentDownload document
Summary
CoW 34/2021 – This case reports on a 18-year-old male patient, who was admitted to a secondary hospital due to febrile symptoms (38.5-39°C) and headache with deterioration of his neurological status (bradypsychia, deviation of gaze and vomiting) after outpatient antibiotic management following suspected neuro-infection.
Case presentation
Known medical history included Marfan syndrome, bacterial endocarditis at the age of 16 as well as mitral valve replacement with a mechanical prosthesis 8 months before the current hospitalization
Antibiotic therapy at this time point consisted of vancomycin (870 mg every 12 hours), rifampicin (300 mg every 8 hours) and gentamicin (60 mg iv every 8 hours)
Following admission, he was evaluated and after diagnostic brain CT imaging and laboratory analysis, initial working diagnosis was either endocarditis and/or septic embolism in the brain
Due to his medical history, he was then referred to the Clínica Colsubsidio Calle 100, Bogota, being a tertiary referral centre
Subsequent transesophageal echocardiography showed preserved contractility and systolic function, with a left ventricular ejection fraction (LVEF) of 58%, mechanical prosthesis in mitral position with elevated transvalvular gradients, echo-dense mass described in anterior portion of prosthetic ring compatible with a vegetation, and at least moderate anterior paravalvular leak
Over the following 4 days, the patient was evaluated for potential surgical treatment. However, due to the unknown etiology of his cerebrovascular event, additional studies were performed including checks for potential infectious diseases (e.g. COVID-19), and more advanced laboratory tests
Contrast magnetic resonance imaging (MRI) then confirmed an ischemic event in the late subacute evolutionary phase of probable embologenic etiology (septic) being the most likely cause, however micro-abscesses were also considered as differential diagnosis
Four days later, further neurological examinations reconfirmed an ischemic acute cerebrovascular event without hemorrhagic transformation and micro-abscesses. The antimicrobial management was deemed appropriate and was proposed to be continued for at least 4 weeks
Prior to surgery, the patient showed profound hemodynamic instability with a decreased systemic vascular resistance index (SVRI, 620 dyn*s*cm5*m²) requiring massive doses of vasopressors (vasopressin 3 IU/h, norepinephrine 0.5 µg/kg/min)
Additionally, hemodynamic disturbances translated into profound lactic acidosis (4.4 mmol/l)
As there were no contraindications for surgery nor for the use of anticoagulants, the redo procedure was scheduled for the next day and consisted of mitral valve replacement (MVR) with a mechanical prosthesis and tricuspid annuloplasty
Given the young age of the patient, his extensive medical history, the infectious profile as well as the hemodynamic instability, a CytoSorb hemoadsorber was integrated into the cardiopulmonary bypass (CPB) circuit with the rationale to stabilize hemodynamics and to reduce the hyperinflammatory response, which was anticipated would be triggered by this major procedure in a patient with considerable cardiac history
Treatment
CytoSorb was used in conjunction with the cardiopulmonary bypass machine (SARNS 8.000, Terumo. Additionally BP-80 Centrifugal pump, Medtronic) for a period of 100 minutes, cross clamp time was 90 min
Anticoagulation: heparin
Blood flow rate: 500 ml/min
ACT: 418 – 527 – 483 – 144 sec
Total heparin: 32,500 IU
Protamine: 30,000 IU
Ultrafiltration rate: 2.200 cc
Administered blood components during surgery: 2x fresh frozen plasma, 6x cryoprecipitate, 1x red blood cell concentrate
Measurements
Hemodynamics and catecholamine requirements
Lactate values
Inflammatory parameters
Postoperative bleeding rate
Results
Perioperatively, his vasopressor demand increased transiently and dobutamine had to be added. However, already 60 minutes after completion of the procedure, dosages of vasopressors could be decreased considerably (vasopressin 1 IU/h, norepinephrine: 0.05 µg/kg/min). Six hours after the procedure, vasopressin and norepinephrine infusion could be stopped and dobutamine was kept at 2.5 µg/kg/min to support contractility
This was accompanied by a decrease in plasma lactate concentrations from 4 mmol/l pre-treatment to 2.9 mmol/l during CPB and 2.5 mmol/l post CPB
Also levels of C-reactive protein (CRP) decreased under CytoSorb therapy: CRP pre 77 mg/l, CRP during CPB 3.3 mg/l, CRP post CPB 2.8 mg/l
Patient Follow-Up
Extubation 12 hours after leaving the operating theatre
Clinical evidence of good peripheral perfusion
No bleeding complications occurred and surgical drains were removed after 48 hours
Examination of valve cultures later confirmed colonization with S. hominis so it was decided to maintain antibiotic treatment with vancomycin for another 6 weeks
The patient developed a complete AV block postoperatively, and the electrophysiology department opted for permanent pacemaker implantation, while neurology recommended continuation of treatment initially in the intensive care unit
Transfer of the patient to the normal ward 6 days after the procedure and back home 9 days later with continued antibiotic and anticoagulation therapy
Conclusion
The intraoperative use of CytoSorb incorporated into the CPB circuit in this patient with infective endocarditis undergoing a mitral valve replacement redo procedure was associated with an improvement of the perioperative hemodynamic situation accompanied by resolution of lactic acidosis and control of the anticipated hyperinflammatory response
Due to the excellent results both in modulation of the inflammatory response and in the postoperative bleeding rate, the surgical team now routinely consider the intraoperative use of CytoSorb in patients with a diagnosis of infective endocarditis
Integration into the CPB circuit was easy and safe. No adverse events were recorded.
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM